hcp.paragard.comParagard® IUD HCP Site

Prescribing Information Patient Site Request a Rep 1-877-PARAGARD (727-2427) Menu About Paragard About Paragard Who Is Right for Paragard? Efficacy Mechanism of Action Patient Satisfaction & Continuation Rates Placement & Training Step-by-step with Paragard IUS Clinical Specialist Education Sessions Ordering & Reimbursement Ordering Reimbursement Cost to Patients Resources Safety Patient Site Request a Rep 1-877-PARAGARD (727-2427) Menu About Paragard About Paragard Who Is Right for Paragard? Efficacy Mechanism of Action Patient Satisfaction & Continuation Rates Placement & Training Step-by-step with Paragard IUS Clinical Specialist Education Sessions Ordering & Reimbursement Ordering Reimbursement Cost to Patients Resources Safety Patient Site Request a Rep 1-877-PARAGARD (727-2427) Learn about single-hand placement with a built-in loading tip GO NOW Their choices change, but one choice is clear: Hormone-Free Paragard ®1 From running the school social scene to running a startup Offer your patients a birth control that won’t interfere with them or their future choices. Paragard is ready for any stage they enter next. Learn More Ordering and Reimbursement Order Now Placement and Removal Training See Options Resources for You and Your Patients Download Now Training Support for Your Practice Request a Placement Training Session In-person or live virtual Request Placement Training & More Watch the Placement Training Video Watch Video Watch Placement Training Video With Single-Hand Insertion Watch VideoX Access our new Online Virtual Training Simulation click hereINDICATIONS AND USAGE Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS The use of Paragard is contraindicated when one or more of the following conditions exist: Pregnancy or suspicion of pregnancy, abnormalities of the uterus resulting in distortion of the uterine cavity, acute pelvic inflammatory disease (PID), postpartum or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUS that has not been removed, hypersensitivity to any component of Paragard including to copper or any of the trace elements present in the copper component of Paragard. Expand INDICATIONS AND USAGE Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS The use of Paragard is contraindicated when one or more of the following conditions exist: Pregnancy or suspicion of pregnancy, abnormalities of the uterus resulting in distortion of the uterine cavity, acute pelvic inflammatory disease (PID), postpartum or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUS that has not been removed, hypersensitivity to any component of Paragard including to copper or any of the trace elements present in the copper component of Paragard. WARNINGS AND PRECAUTIONS Ectopic Pregnancy : Evaluate for possible ectopic pregnancy in any female who becomes pregnant while using Paragard. Intrauterine Pregnancy : Failure to remove Paragard increases the risk of miscarriage, sepsis, premature labor, and premature delivery. Sepsis : Severe infection or sepsis, including Group A Streptococcal Sepsis (GAS), have been reported following insertion of IUSs, including Paragard. Pelvic Inflammatory Disease and Endometritis : Remove Paragard in cases of recurrent PID or endometritis, or if an acute pelvic infection is severe or does not respond to treatment. Embedment : Partial penetration or embedment of Paragard in the myometrium can make removal difficult; surgical removal may be necessary. Breakage of an embedded Paragard during non-surgical removal has been reported. Perforation : Partial or total perforation of the uterine wall or cervix may reduce contraceptive efficacy and result in pregnancy. Delayed detection or removal of Paragard may result in migration outside the uterine cavity, adhesions, peritonitis, intestinal penetration, intestinal obstruction, abscesses and/or damage to adjacent organs. Increased risk when the uterus is fixed, retroverted or not completely involuted during the postpartum period. If perforation does occur, locate and remove Paragard promptly. Expulsion : Partial or complete expulsion of Paragard has been reported, resulting in the loss of contraceptive protection. The risk of expulsion may be increased when the uterus is not completely involuted at the time of insertion. Remove a partially expelled Paragard. Wilson’s Disease : Paragard may exacerbate Wilson’s disease. Bleeding Pattern Alterations : Paragard can alter the bleeding pattern and result in heavier and longer menstrual cycles with intermenstrual spotting. Magnetic Resonance Imaging (MRI) Safety Information : Non-clinical testing has demonstrated that Paragard is MR Conditional. Medical Diathermy : Avoid using high medical RF transmitter devices in females with Paragard. ADVERSE REACTIONS Adverse reactions reported in clinical trials include anemia, backache, dysmenorrhea, dyspareunia, expulsion (complete or partial), prolonged menstrual flow, menstrual spotting, pain and cramping, and vaginitis. INDICATIONS AND USAGE Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. Please see full Prescribing Information . References: 1. Paragard® Package Insert, Trumbull, CT: CooperSurgical, Inc. July 2021. 2. Hubacher D, Schreiber CA, Turok DK, et al. Continuation rates of two different-sized copper intrauterine devices among nulliparous women: interim 12-month results of a single-blind, randomised, multicentre trial. eClinicalMedicine. 2022;51:101554. Cookie SettingsTerms of Use Privacy Notice Modern Slavery Act Contact Us Data Privacy Policy Do Not Sell/Do Not Share Cookie Preferences Cookie Policy Paragard ® and Paragard Access Center ® are registered trademarks, and Paragard Direct ℠ and Paragard Specialty Pharmacy ℠ are service marks of CooperSurgical, Inc. © 2024 CooperSurgical, Inc. C-US-PAR-000340 January 2024 THIS SITE IS INTENDED FOR RESIDENTS OF THE UNITED STATES ONLY. The information you have requested is intended for US Healthcare Professionals only. Please continue to the Healthcare Professional site if you are a Healthcare Professional. Healthcare Professional Site Patient Site × For updates on the Paragard ® IUS, including placement training, please sign up for our mailing list. First Name Last Name Email Please send important news, updates, and promotions from CooperSurgical to my email address, provided above By subscribing, you agree to our Data Privacy Policy and our Terms and Conditions . × To be notified of placement training opportunities and product updates Sign...